Table 3.
SARS-CoV-2 neutralising antibody titres (MNT50 assay) and binding antibody responses (ELISA; S1 protein, RBD, and N protein IgGs)
| BBV152: lot 1 | BBV152: lot 2 | BBV152: lot 3 | BBV152: all lots | Placebo | |
|---|---|---|---|---|---|
| SARS-CoV-2 neutralising antibody | |||||
| Day 0: participants | 132 | 129 | 136 | 397 | 125 |
| Day 0: GMT (95% CI) | 9·9 (8·3–11·9) | 8·6 (7·5–9·9) | 7·9 (7·0–8·9) | 8·8 (8·0–9·6) | 8·9 (7·7–10·4) |
| Day 56: participants | 128 | 125 | 133 | 386 | 119 |
| Day 56: GMT (95% CI) | 130·3 (105·8–160·4) | 121·2 (97·6–150·5) | 125·4 (101·3–155·1) | 125·6 (111·2–141·8) | 13·7 (10·7–170·4) |
| S1 protein-binding IgG | |||||
| Day 56: participants | 129 | 124 | 134 | 387 | 121 |
| Day 56: GMT (95% CI) | 9760 (8483–11 228) | 10 404 (8873–12 198) | 9152 (7912–10 586) | 9742 (8949–10 606) | 1528 (1323–1765) |
| RBD-binding IgG | |||||
| Day 56: participants | 129 | 124 | 134 | 387 | 121 |
| Day 56: GMT (95% CI) | 4266 (3584–5079) | 4423 (3669–5333) | 3740 (3180–4399) | 4124 (3731–4557) | 1443 (1261–1651) |
| N protein-binding IgG | |||||
| Day 56: participants | 129 | 124 | 134 | 387 | 121 |
| Day 56: GMT (95% CI) | 4551 (3800–5450) | 4183 (3423–5111) | 3798 (3165–4558) | 4161 (3736–4633) | 1485 (1275–1730) |
Data are shown for neutralising antibody response expressed as MNT50 at day 0 (baseline) and day 56 (4 weeks after the second vaccination). Day 56 IgG antibody titres are expressed as arbitrary ELISA units per mL, all baseline titres being at the cutoff for the assay (reciprocal of 1:500 dilution). GMT=geometric titre. MNT50=microneutralisation titre 50%. N protein=nucleocapsid protein. RBD=receptor-binding domain. S1=spike protein S1 subunit.